GF9 is a TREM-1 inhibitor that targets transmembrane structural domains that was discovered by Sigalov et al. [132], and its effectiveness has been demonstrated in animal models of arthritis [133], alcoholic liver disease [134], pertussis [135], and pancreatic cancer [136]. The gene discussed is TREM1; the disease is Arthritis.